Nick Abbott
Stock Analyst at Wells Fargo
(0.10)
# 4,359
Out of 4,984 analysts
5
Total ratings
25%
Success rate
-33.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nick Abbott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Overweight | $45 → $9 | $15.87 | -43.29% | 1 | Oct 4, 2022 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $450 | $2.40 | +18,650.00% | 2 | Oct 4, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $7 → $1.5 | $0.08 | +1,756.44% | 1 | Oct 4, 2022 | |
| CLLS Cellectis | Downgrades: Equal-Weight | $16 | $3.08 | +419.48% | 1 | Jan 6, 2022 |
Zymeworks
Oct 4, 2022
Assumes: Overweight
Price Target: $45 → $9
Current: $15.87
Upside: -43.29%
Alaunos Therapeutics
Oct 4, 2022
Assumes: Overweight
Price Target: $450
Current: $2.40
Upside: +18,650.00%
Adaptimmune Therapeutics
Oct 4, 2022
Maintains: Equal-Weight
Price Target: $7 → $1.5
Current: $0.08
Upside: +1,756.44%
Cellectis
Jan 6, 2022
Downgrades: Equal-Weight
Price Target: $16
Current: $3.08
Upside: +419.48%